TrialBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2024

Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study.

Kim A Papp et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.